Abstract: Hepatocellular carcinoma (HCC) primarily relies on surgical resection for curative treatment,but the high recurrence rate after surgery is a pressing issue that needs to be addressed.Neoadjuvant immunotherapy,represented by immune checkpoint inhibitors (ICIs),has the potential to reduce postoperative recurrence,increase the rate of radical resection,and prolong survival time.The combination of ICIs with other treatments is gradually becoming a hot area in clinical research for liver cancer.

Key words: hepatocellular carcinoma;neoadjuvant therapy;immune checkpoint inhibitors